钆塞酸增强MRI能否预测大范围肝切除术后肝衰竭及其他并发症?
研究纳入65例连续接受肝切除术前钆塞酸增强MRI的患者,计算相对肝脏强化(RLE)和未来残肝(FLR)比率。RLE预测肝切除术后肝衰竭(PHLF)的AUROC为0.665,与FLR比率(0.705)相当,但预测其他主要并发症(OMC)表现不佳(AUROC 0.556 vs 0.702)。联合所有临床和影像参数预测PHLF和OMC的AUROC分别为0.875和0.742。
要点
- RLE预测PHLF的AUROC为0.665,与FLR比率0.705相当。
- RLE预测OMC的AUROC仅0.556,FLR比率为0.702。
- 联合临床参数、FLR比率和RLE预测PHLF的AUROC达0.875。
核心结论
- 基于临床参数、FLR比率和钆塞酸RLE的模型可能改善肝切除术前风险评估。
研究设计与样本
- 纳入65例2010年10月至2013年12月间连续接受肝切除术前钆塞酸增强MRI的患者,RLE由MRI感兴趣区计算,FLR比率来自CT,PHLF按国际肝脏外科研究组标准定义,OMC按Clavien-Dindo分级≥3定义,采用多因素logistic回归建模。
关键影像表现/征象
- RLE由MRI感兴趣区计算,FLR比率由CT获得。
- 预测PHLF的AUROC:RLE 0.665,FLR比率0.705。
- 预测OMC的AUROC:RLE 0.556,FLR比率0.702。
- 联合所有临床和影像参数预测PHLF的AUROC为0.875,预测OMC的AUROC为0.742。
诊断标准与关键数值
- PHLF按国际肝脏外科研究组标准定义。
- OMC按Clavien-Dindo分级≥3定义。
- RLE预测PHLF的AUROC为0.665,FLR比率为0.705。
- RLE预测OMC的AUROC为0.556,FLR比率为0.702。
- 联合所有临床和影像参数预测PHLF的AUROC为0.875,预测OMC的AUROC为0.742。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To determine whether a combination of clinical factors, the future liver remnant (FLR) ratio, and hepatic uptake of gadoxetic acid can be used to predict post-hepatectomy liver failure (PHLF) and other major complications (OMC).
MATERIALS AND METHODS: Sixty-five consecutive patients who underwent pre-hepatectomy gadoxetic acid-enhanced magnetic resonance imaging (MRI) between October 2010 and December 2013 were included. The relative liver enhancement (RLE) of gadoxetic acid was calculated from regions of interest on MRI, and FLR ratios were obtained from computed tomography (CT). PHLF and OMC were defined by the International Study Group of Liver Surgery criteria and Clavien-Dindo grade of ≥3, respectively. Multivariate logistic regression modelling was performed to identify predictors of PHLF and OMC, including RLE, FLR ratio, age, sex, chemotherapy history, intra-operative blood loss, and intra-operative transfusion.
RESULTS: Nine patients experienced PHLF and another nine patients experienced OMC. RLE was comparable to the FLR ratio in predicting PHLF (areas under the receiver operating characteristic [AUROC] curves, 0.665 and 0.705), but performed poorly in predicting OMCs (AUROCs, 0.556 and 0.702). Combining all clinical and imaging parameters as predictors yielded the best performing predictive models (AUROCs, 0.875 and 0.742 for PHLF and OMC, respectively).
CONCLUSION: A model based on clinical parameters, the FLR ratio, and RLE of gadoxetic acid may improve pre-hepatectomy risk assessment.
引用
- Costa AF, Tremblay St-Germain A, Abdolell M, et al. Can contrast-enhanced MRI with gadoxetic acid predict liver failure and other complications after major hepatic resection? Clin Radiol. 2017. PMID: 28274510. doi:10.1016/j.crad.2017.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。